Intratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma.

ABSTRACT:

Purpose

Activation of STING (stimulator of interferon genes) can trigger a robust, innate antitumor immune response in immunologically "cold" tumors such as glioblastoma.

Patients and methods

A small-molecule STING agonist, IACS-8779, was stereotactically administered using intraoperative navigation intratumorally in dogs with spontaneously arising glioblastoma. The phase I trial used an escalating dose design, ascending through four dose levels (5-20 μg). Treatment was repeated every 4-6 weeks for a minimum of two cycles. Radiographic response to treatment was determined by response assessment in neuro-oncology (RANO) criteria applied to isovoxel postcontrast T1-weighted MR images obtained on a single 3T magnet.

Results

Six dogs were enrolled and

SUBMITTER: Boudreau CE 

PROVIDER: S-EPMC8989401 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature